Yoshinori Mori

Yoshinori Mori

Auto-generated profile, based on publicly available information

Yoshinori Mori

Department of Gastroenterology, Nagoya City University West Medical Center

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MTMamoru Tanaka
Mamoru Tanaka
HKHiromi Kataoka
Hiromi Kataoka
SYShigenobu Yano
Shigenobu Yano
HOHiromi Ohi
Hiromi Ohi
KKKeisuke Kawamoto
Keisuke Kawamoto
TJTakashi Joh
Takashi Joh
Background: Cisplatin (CDDP) is the most frequently used chemotherapeutic agent for various types of advanced cancer, including gastric cancer. However, almost all cancer cells acquire resistance against CDDP, and this phenomenon adversely affects prognosis. Thus, new chemotherapeutic agents that can overcome the CDDP-resistant cancer cells will improve the survival of advanced cancer patients. Methods: We synthesized new glycoconjugated platinum (II) and palladium (II) complexes, [PtCl2 (L)] and [PdCl2 (L)]. CDDP-resistant gastric cancer cell lines were established by continuous exposure to CDDP, and gene expression in the CDDP-resistant gastric cancer cells was analyzed. The cytotoxicity and apoptosis induced by [PtCl2 (L)] and [PdCl2 (L)] in CDDP-sensitive and CDDP-resistant gastric cancer cells were evaluated. DNA double-strand breaks by drugs were assessed by evaluating phosphorylated histone H2AX. Xenograft tumor mouse models were established and antitumor effects were also examined in vivo. Results: CDDP-resistant gastric cancer cells exhibit ABCB1 and CDKN2A gene up-regulation, as compared with CDDP-sensitive gastric cancer cells. In the analyses of CDDP-resistant gastric cancer cells, [PdCl2 (L)] overcame cross-resistance to CDDP in vitro and in vivo. [PdCl2 (L)] induced DNA double-strand breaks. Conclusion: These results indicate that [PdCl2 (L)] is a potent chemotherapeutic agent for CDDP-resistant gastric cancer and may have clinical applications.

1 August 2010 in The American Journal of Pathology
Verified
Journal Article
Open access
PDF file
EKEiji Kubota
Eiji Kubota
HKHiromi Kataoka
Hiromi Kataoka
MAMineyoshi Aoyama
Mineyoshi Aoyama
TMTsutomu Mizoshita
Tsutomu Mizoshita
YMYoshinori Mori
Yoshinori Mori
TJTakashi Joh
Takashi Joh
ERas, a unique member of the Ras family, was initially found only in embryonic stem (ES) cells, where it plays a crucial role in the transformation of transplanted ES cells to teratomas. ERas is involved in ES cell survival, and unlike other Ras family members, is constitutively active without any mutations. The aim of this study was to investigate the expression and role of ERas in human gastric cancer. To test whether ERas played a significant role in human cancer cells, we examined its expression and function in gastric cancer. ERas was expressed in gastric cancer cell lines at different levels. Induction of ERas expression activated the phosphatidylinositol 3 kinase (PI3K)/Akt axis and then enhanced anchorage-independent growth and ERas knockdown by siRNA suppressed cell invasion. Immunohistochemical analyses revealed that ERas was expressed in 38.7% (55/142) of human gastric carcinoma tissues, and its expression was significantly associated with metastasis to the liver (P < 0.0001) and lymph nodes (P < 0.05). ERas up-regulated transcription regulatory factors including ZFHX1A, ZFHX1B, and TCF3, which repress E-cadherin. These data suggest that ERas is activated in a significant population of gastric cancer, where it may play a crucial role in gastric cancer cell survival and metastases to liver via down-regulation of E-cadherin.

1 March 2013 in Catalysis Today
Verified
Journal Article
Closed access
AYAkihiro Yoshida
Akihiro Yoshida
YMYoshinori Mori
Yoshinori Mori
TITsuyoshi Ikeda
Tsuyoshi Ikeda
KAKazuki Azemoto
Kazuki Azemoto
Shuichi NaitoShuichi Naito
Shuichi Naito

22 March 2016 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
HKHiromi Kataoka
Hiromi Kataoka
YMYoshinori Mori
Yoshinori Mori
Takaya ShimuraTakaya Shimura
Takaya Shimura
HNHirotada Nishie
Hirotada Nishie
MNMakoto Natsume
Makoto Natsume
TJTakashi Joh
Takashi Joh

1 January 2022
Verified
Journal Article
Closed access
YTYusaku Tomita
Yusaku Tomita
YMYoshinori Mori
Yoshinori Mori
HKHiroki Kanaiwa
Hiroki Kanaiwa
AYAyana Yamaguchi
Ayana Yamaguchi
MKMika Kitagawa
Mika Kitagawa
KSKyoji Seno
Kyoji Seno